A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase.

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Donepezil (Primary)
  • Indications Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 14 Apr 2016 According to an Eisai Co Ltd media release, donepezil hydrochloride (Aricept) has been approved in Japan to include treatment of dementia with Lewy bodies.
    • 14 Apr 2016 According to an Eisai Co Ltd media release, donepezil hydrochloride (Aricept) has been approved in Philippines for the symptomatic treatment of dementia with Lewy bodies.
    • 27 Nov 2015 Treatment arms changed from 3 to 5 with addition of Donepezil (5 +10 mg) - Extension Phase as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top